According to the company, this expands the initial CE Mark approval of the Mirasol pathogen reduction technology (PRT) system for platelets granted in October 2007.
The company can now begin marketing and selling the Mirasol PRT system to reduce the active pathogen load and neutralize white blood cells in donor plasma for transfusion in various geographies in Europe, Africa, and the Middle East.
The Mirasol PRT system is a new technology based on ultraviolet light and riboflavin (vitamin B2) that has the potential to inactivate pathogens in all three major blood components – platelets, plasma, and red blood cells.
Teresa Ayers, senior vice president and general manager of pathogen reduction technologies at CaridianBCT, said: “Based on safe, simple, and efficient methods using naturally occurring riboflavin (vitamin B2) and UV light, the Mirasol PRT system fits easily into our customers’s workflow allowing for rapid release of platelets and plasma after illumination.”